Laryngeal CancerSymptoms, Doctors, Treatments, Advances & More
Laryngeal Cancer Overview
Learn About Laryngeal Cancer
Johns Hopkins Outpatient Center
Christine Gourin, M.D. M.P.H., is a head and neck surgical oncologist and palliative medicine specialist who treats patients with head and neck tumors, including tumors of the skin, melanoma, oral cavity, larynx, oropharynx, neck, salivary glands, sinuses, and skull base. Dr. Gourin received her medical degree from the State University of New York-Health Science Center at Brooklyn/Downstate Medical Center. Dr. Gourin trained in General Surgery and Otolaryngology-Head and Neck Surgery at the University of Vermont, followed by a fellowship in Advanced Head and Neck Oncologic Surgery at the University of Pittsburgh and a fellowship in Hospice and Palliative Medicine at Johns Hopkins University. She has authored over 200 peer-reviewed journal articles, 24 book chapters and two books: Medical and Surgical Management of Thyroid and Parathyroid Diseases and The Johns Hopkins Patient Guide to Head and Neck Cancer. She is on the Editorial Board of The Laryngoscope and is a reviewer for numerous other head and neck surgery journals. Dr. Gourin is a nationally and internationally recognized expert in quality of care and outcomes with a lifelong interest in improved symptom management, communication, access to high-quality affordable care, and palliative medicine in head and neck cancer. She has an active head and neck surgical oncology practice and has been named to America’s Top Physicians and Best Doctors in America annually since 2005. She is the Director of the Johns Hopkins Head and Neck Cancer Supportive Care Clinic. Dr. Gourin is rated as an Elite provider by MediFind in the treatment of Laryngeal Cancer. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Tongue Cancer, Laryngectomy, and Gastrostomy. Dr. Gourin is board certified in American Board Of Internal Medicine and Head And Neck Surgery.
Cleveland Clinic Main Campus
Joseph Scharpf is an Otolaryngologist practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 32 years. Dr. Scharpf is rated as an Elite provider by MediFind in the treatment of Laryngeal Cancer. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Human Papillomavirus Infection, Thyroidectomy, and Laryngectomy. Dr. Scharpf is board certified in American Board Of Otolaryngology, 2005.
Univ. Ear Nose & Throat Specialists - Eye And Ear Inst.
Matthew E. Spector, MD, FACS, completed his medical school training at Stritch School of Medicine, Loyola University in Chicago. He then went on to the University of Michigan where he completed his residency in Otolaryngology – Head and Neck Surgery and fellowship in Head and Neck Surgical Oncology and Microvascular Reconstruction. He was on faculty at the University of Michigan for 10 years where he served as the Director of the Head and Neck Oncology Program and Associate Director of the Head and Neck Surgical Oncology and Microvascular Reconstruction Fellowship. Dr. Spector is rated as an Elite provider by MediFind in the treatment of Laryngeal Cancer. He is also highly rated in 33 other conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Tongue Cancer, Laryngectomy, and Glossectomy. Dr. Spector is board certified in American Board Of Otolaryngology - Head And Neck Surgery. Dr. Spector is currently accepting new patients.
Summary: This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. CDX-1140 is a monoclonal antibo...
Summary: To find the highest tolerable dose of stereotactic hypofractionated radioablation (HYDRA) radiation that can be given to patients with laryngeal cancer. The safety of this radiation will also be studied.


